Celgene Can't Delay Cancer Drug Antitrust Case, Court Told
Drug payors pressed a New Jersey federal judge Thursday not to let Celgene Corp. and parent Bristol-Myers Squibb Co. "delay justice and perpetuate the illegal conduct" preventing generic competition for two...To view the full article, register now.
Already a subscriber? Click here to view full article